BACKGROUND: In breast-feeding populations, immunization during pregnancy with pneumococcal polysaccharide offers a potentially useful approach to preventing pneumococcal disease in young infants. METHODS: Breast milk samples were collected at 0, 2, 4 and 6 months after delivery from Gambian women vaccinated during pregnancy (24-32 weeks gestation) with Pneumovax II (n = 56) or Mengivax A&C (n = 57). Specimens were examined for secretory immunoglobulin A (s-IgA) concentration, subclass distribution and avidity specific to pneumococcal serotypes 4, 6B, 14, 19F and 23F and the antigen mixture in Pneumovax II by enzyme-linked immunosorbent assay. Colostral s-IgA and IgG concentrations in paired maternal sera were compared. RESULTS: Colostral s-IgA concentrations specific to all pneumococcal polysaccharide antigens investigated were significantly higher (P < 0.05) among Pneumovax II vaccinees. Titers specific to serotypes 4, 6B and 14 and the vaccine formula remained significantly higher during 6 months, and those for 19F were higher during 4 months. Significantly higher concentrations of vaccine antigen-specific s-IgA antibody were sustained for 6 months after delivery (P = 0.011). Comparison of colostral s-IgA and IgG in serum revealed a significant correlation only among Mengivax A&C vaccinees for pneumococcal polysaccharide 23F (rs= 0.68; P < or = 0.0001). Vaccination elicited trends toward increased s-IgA2, reaching significance for serotype 14 and the vaccine formula. Immunization elicited significantly higher s-IgA avidities specific to all pneumococcal polysaccharide antigens studied during 6 months. CONCLUSIONS: The public health value of immunization during pregnancy with pneumococcal polysaccharide vaccine in breast-feeding populations warrants further evaluation, particularly in populations with a high incidence of pneumococcal disease in early infancy.
RCT Entities:
BACKGROUND: In breast-feeding populations, immunization during pregnancy with pneumococcalpolysaccharide offers a potentially useful approach to preventing pneumococcal disease in young infants. METHODS: Breast milk samples were collected at 0, 2, 4 and 6 months after delivery from Gambian women vaccinated during pregnancy (24-32 weeks gestation) with Pneumovax II (n = 56) or Mengivax A&C (n = 57). Specimens were examined for secretory immunoglobulin A (s-IgA) concentration, subclass distribution and avidity specific to pneumococcal serotypes 4, 6B, 14, 19F and 23F and the antigen mixture in Pneumovax II by enzyme-linked immunosorbent assay. Colostral s-IgA and IgG concentrations in paired maternal sera were compared. RESULTS: Colostral s-IgA concentrations specific to all pneumococcalpolysaccharide antigens investigated were significantly higher (P < 0.05) among Pneumovax II vaccinees. Titers specific to serotypes 4, 6B and 14 and the vaccine formula remained significantly higher during 6 months, and those for 19F were higher during 4 months. Significantly higher concentrations of vaccine antigen-specific s-IgA antibody were sustained for 6 months after delivery (P = 0.011). Comparison of colostral s-IgA and IgG in serum revealed a significant correlation only among Mengivax A&C vaccinees for pneumococcalpolysaccharide 23F (rs= 0.68; P < or = 0.0001). Vaccination elicited trends toward increased s-IgA2, reaching significance for serotype 14 and the vaccine formula. Immunization elicited significantly higher s-IgA avidities specific to all pneumococcalpolysaccharide antigens studied during 6 months. CONCLUSIONS: The public health value of immunization during pregnancy with pneumococcalpolysaccharide vaccine in breast-feeding populations warrants further evaluation, particularly in populations with a high incidence of pneumococcal disease in early infancy.
Authors: Marinos C Makris; Konstantinos A Polyzos; Michael N Mavros; Stavros Athanasiou; Petros I Rafailidis; Matthew E Falagas Journal: Drug Saf Date: 2012-01-01 Impact factor: 5.606
Authors: Alexandra Bonner; Adel Almogren; Patricia B Furtado; Michael A Kerr; Stephen J Perkins Journal: J Biol Chem Date: 2008-12-23 Impact factor: 5.157
Authors: Pia S Pannaraj; André Guilherme da Costa-Martins; Chiara Cerini; Fan Li; Sook-San Wong; Youvika Singh; Alysson H Urbanski; Patrícia Gonzalez-Dias; Juliana Yang; Richard J Webby; Helder I Nakaya; Grace M Aldrovandi Journal: Mucosal Immunol Date: 2022-06-23 Impact factor: 8.701
Authors: Martin O C Ota; Anna Roca; Christian Bottomley; Philip C Hill; Uzochukwu Egere; Brian Greenwood; Richard A Adegbola Journal: PLoS One Date: 2012-08-14 Impact factor: 3.240
Authors: Uzochukwu Egere; John Townend; Anna Roca; Abiodun Akinsanya; Abdoulie Bojang; David Nsekpong; Brian Greenwood; Richard A Adegbola; Philip C Hill Journal: PLoS One Date: 2012-11-21 Impact factor: 3.240